Tenax Therapeutics is a pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases. Through its wholly owned subsidiary, Life Newco, Inc. (Life Newco), Co. owns a license granting Life Newco a sublicenseable right to develop and commercialize pharmaceutical products containing levosimendan, 2.5 mg/ml concentrate for solution for infusion / 5ml vial in the U.S. and Canada. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure. The TENX stock yearly return is shown above.
The yearly return on the TENX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2019 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the TENX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|